More than 75 million people worldwide have been infected with human immunodeficiency virus (HIV), and there are now approximately 37 million individuals living with the infection. Untreated HIV replication causes progressive CD4+ T cell loss and a wide range of immunological abnormalities, leading to an increased risk of infectious and oncological complications. HIV infection also contributes to cardiovascular disease, bone disease, renal and hepatic dysfunction and several other common morbidities. Antiretroviral drugs are highly effective at inhibiting HIV replication, and for individuals who can access and adhere to these drugs, combination antiretroviral therapy leads to durable (and probably lifelong) suppression of viral replication. Viral suppression enables immune recovery and the near elimination of the risk for developing acquired immune deficiency syndrome (AIDS). Despite effective treatment, HIV-infected individuals have a higher than expected risk of heart, bone, liver, kidney and neurological disease. When used optimally by an infected (or by an uninfected) person, antiretroviral drugs can virtually eliminate the risk of HIV transmission. Despite major advances in prevention sciences, HIV transmission remains common in many vulnerable populations, including men who have sex with men, injection drug users and sex workers. Owing to a lack of widespread HIV testing and the costs and toxicities associated with antiretroviral drugs, the majority of the infected population is not on effective antiretroviral therapy. To reverse the pandemic, improved prevention, treatment and implementation approaches are necessary.
Subscribe to Journal
Get full journal access for 1 year
only $65.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Faria, N. R. et al. HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations. Science 346, 56–61 (2014).
Keele, B. F. et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313, 523–526 (2006).
Gottlieb, M. S. et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 305, 1425–1431 (1981).
Barre-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868–871 (1983).
Gallo, R. C. et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220, 865–867 (1983).
UN Joint Programme on HIV/AIDS. MDG 6: 15 years, 15 lessons of hope from the AIDS response. Fact sheet. UNAIDS[online], (2015).
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385, 117–171 (2015).
Moir, S., Chun, T. W. & Fauci, A. S. Pathogenic mechanisms of HIV disease. Annu. Rev. Pathol. 6, 223–248 (2011).
Haase, A. T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 5, 783–792 (2005).
Mellors, J. W. et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167–1170 (1996).
McCune, J. M. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 410, 974–979 (2001).
Deeks, S. G. & Walker, B. D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27, 406–416 (2007).
Davey, R. T. Jr et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sci. USA 96, 15109–15114 (1999).
UN Joint Programme on HIV/AIDS. The Gap Report. Refworld[online], (2014). With a global modelling effort, UNAIDS produce detailed estimates of trends in the pandemic that are crucial for global advocacy.
Beyrer, C. et al. The increase in global HIV epidemics in MSM. AIDS 27, 2665–2678 (2013).
UN Joint Programme on HIV/AIDS. Global Report. UNAIDS reports on the global AIDS epidemic 2013. UNAIDS[online], (2013).
Shisana, O. et al. South African National HIV Prevalence, Incidence and Behaviour Survey, 2012 (HSRC Press, 2014).
Gregson, S. et al. HIV decline in Zimbabwe due to reductions in risky sex? Evidence from a comprehensive epidemiological review. Int. J. Epidemiol. 39, 1311–1323 (2010).
Rosen, S. & Fox, M. P. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 8, e1001056 (2011).
McMahon, J. H., Elliott, J. H., Hong, S. Y., Bertagnolio, S. & Jordan, M. R. Effects of physical tracing on estimates of loss to follow-up, mortality and retention in low and middle income country antiretroviral therapy programs: a systematic review. PLoS ONE 8, e56047 (2013).
Wu, L. & KewalRamani, V. N. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 6, 859–868 (2006).
Zeng, M. et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J. Clin. Invest. 121, 998–1008 (2011).
Estes, J. D. et al. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor β1-positive regulatory T cells and begins in early infection. J. Infect. Dis. 195, 551–561 (2007).
Sanchez, J. L. et al. Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions. J. Infect. Dis. 211, 1068–1075 (2015).
Zeng, M. et al. Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog. 8, e1002437 (2012).
Overbaugh, J. & Bangham, C. R. Selection forces and constraints on retroviral sequence variation. Science 292, 1106–1109 (2001).
Shankarappa, R. et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73, 10489–10502 (1999).
Piantadosi, A. et al. HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response. AIDS 23, 579–587 (2009).
Korber, B. et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58, 19–42 (2001).
Spira, A. I. et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183, 215–225 (1996).
Zhang, Z. et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286, 1353–1357 (1999).
Miller, C. J. et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 79, 9217–9227 (2005).
Sagar, M. HIV-1 transmission biology: selection and characteristics of infecting viruses. J. Infect. Dis. 202, S289–S296 (2010).
Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552–7557 (2008).
Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S. & Landau, N. R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185, 621–628 (1997).
Scarlatti, G. et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3, 1259–1265 (1997).
Long, E. M., Rainwater, S. M., Lavreys, L., Mandaliya, K. & Overbaugh, J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retroviruses 18, 567–576 (2002).
Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273, 1856–1862 (1996).
Sheppard, H. W. et al. HIV-1 infection in individuals with the CCR5-Δ32/Δ32 genotype: acquisition of syncytium-inducing virus at seroconversion. J. Acquir. Immune Defic. Syndr. 29, 307–313 (2002).
Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367–377 (1996).
Samson, M. et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722–725 (1996).
Sagar, M. Origin of the transmitted virus in HIV infection: infected cells versus cell-free virus. J. Infect. Dis. 210, S667–S673 (2014).
Redd, A. D. et al. Previously transmitted HIV-1 strains are preferentially selected during subsequent sexual transmissions. J. Infect. Dis. 206, 1433–1442 (2012).
Derdeyn, C. A. et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303, 2019–2022 (2004).
Chohan, B. et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1–V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J. Virol. 79, 6528–6531 (2005).
Gnanakaran, S. et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 7, e1002209 (2011).
Fenton-May, A. E. et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 10, 146 (2013).
Parrish, N. F. et al. Phenotypic properties of transmitted founder HIV-1. Proc. Natl Acad. Sci. USA 110, 6626–6633 (2013).
Stacey, A. R. et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 83, 3719–3733 (2009).
Sandler, N. G. et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601–605 (2014).
Kelley, C. F., Barbour, J. D. & Hecht, F. M. The relation between symptoms, viral load, and viral load set point in primary HIV infection. J. Acquir. Immune Defic. Syndr. 45, 445–448 (2007).
Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650–4655 (1994).
Richardson, B. A. et al. Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J. Virol. 77, 7120–7123 (2003).
Lyles, R. H. et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J. Infect. Dis. 181, 872–880 (2000).
Kimata, J. T., Kuller, L., Anderson, D. B., Dailey, P. & Overbaugh, J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 5, 535–541 (1999).
Hecht, F. M. et al. HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS 24, 941–945 (2010).
Obimbo, E. M. et al. Pediatric HIV-1 in Kenya: pattern and correlates of viral load and association with mortality. J. Acquir. Immune Defic. Syndr. 51, 209–215 (2009).
Fraser, C. et al. Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective. Science 343, 1243727 (2014).
Alizon, S. et al. Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog. 6, e1001123 (2010).
Buzon, M. J. et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat. Med. 20, 139–142 (2014).
Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893–900 (2009).
Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295 (1997).
Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183–188 (1997).
Chun, T. W. et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc. Natl Acad. Sci. USA 95, 8869–8873 (1998).
Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74–77 (2014).
Buzon, M. J. et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 16, 460–465 (2010).
Hatano, H. et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV Infection: a randomized, placebo-controlled trial. J. Infect. Dis. 208, 1436–1442 (2013).
Fletcher, C. V. et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl Acad. Sci. USA 111, 2307–2312 (2014).
Fukazawa, Y. et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 21, 132–139 (2015).
Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9, 727–728 (2003). This longitudinal study demonstrates that HIV persists at low levels indefinitely even during effective combination ART. Antiretroviral drugs must, therefore, be given indefinitely to prevent viral rebound.
Fellay, J. et al. A whole-genome association study of major determinants for host control of HIV-1. Science 317, 944–947 (2007).
Pereyra, F. et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330, 1551–1557 (2010).
Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350–354 (2006).
Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8+T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198–1202 (2006).
Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381–385 (2015).
Lewis, G. K. Role of Fc-mediated antibody function in protective immunity against HIV-1. Immunology 142, 46–57 (2014).
Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307–312 (2003).
West, A. P. Jr et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156, 633–648 (2014).
Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646–650 (2002).
Laguette, N. et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474, 654–657 (2011).
Neil, S. J., Zang, T. & Bieniasz, P. D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425–430 (2008).
Schwartz, O., Marechal, V., Le Gall, S., Lemonnier, F. & Heard, J. M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 2, 338–342 (1996).
Redd, A. D., Quinn, T. C. & Tobian, A. A. Frequency and implications of HIV superinfection. Lancet Infect. Dis. 13, 622–628 (2013).
Ronen, K. et al. HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog. 9, e1003593 (2013).
Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365–1371 (2006).
Giorgi, J. V. et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J. Acquir. Immune Defic. Syndr. 29, 346–355 (2002).
Deeks, S. G. et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104, 942–947 (2004).
Doitsh, G. et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505, 509–514 (2014).
Quinn, T. C. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N. Engl. J. Med. 342, 921–929 (2000).
Baeten, J. M. et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci. Transl. Med. 3, 77ra29 (2011).
Rottingen, J. A., Cameron, D. W. & Garnett, G. P. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex. Transm. Dis. 28, 579–597 (2001).
Weiss, H. A., Quigley, M. A. & Hayes, R. J. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 14, 2361–2370 (2000).
Lemos, M. P. et al. The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier. PLoS ONE 9, e108954 (2014).
Hirbod, T. et al. HIV acquisition is associated with increased antimicrobial peptides and reduced HIV neutralizing IgA in the foreskin prepuce of uncircumcised men. PLoS Pathog. 10, e1004416 (2014).
Dinh, M. H. et al. Visualization of HIV-1 interactions with penile and foreskin epithelia: clues for female-to-male HIV transmission. PLoS Pathog. 11, e1004729 (2015).
Polis, C. B. & Curtis, K. M. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect. Dis. 13, 797–808 (2013). This is an excellent synthesis of the evidence for and against the role of hormonal contraception increasing HIV infection acquisition in women.
Carnegie, N. B. & Morris, M. Size matters: concurrency and the epidemic potential of HIV in small networks. PLoS ONE 7, e43048 (2012).
New York State Department of Health. Quick reference guide — laboratory testing for the diagnosis of HIV infection: updated recommendations. CDC[online], (2014).
Gokengin, D. et al. 2014 European guideline on HIV testing. Int. J. STD AIDS 25, 695–704 (2014).
Hollingsworth, T. D., Anderson, R. M. & Fraser, C. HIV-1 transmission, by stage of infection. J. Infect. Dis. 198, 687–693 (2008).
Bellan, S. E., Dushoff, J., Galvani, A. P. & Meyers, L. A. Reassessment of HIV-1 acute phase infectivity: accounting for heterogeneity and study design with simulated cohorts. PLoS Med. 12, e1001801 (2015).
Hollingsworth, T. D., Pilcher, C. D., Hecht, F. M., Deeks, S. G. & Fraser, C. High transmissibility during early HIV infection among men who have sex with men — San Francisco, California. J. Infect. Dis. 211, 1757–1760 (2015).
Marks, G., Crepaz, N. & Janssen, R. S. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 20, 1447–1450 (2006).
Pilcher, C. D. et al. Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco. PLoS ONE 8, e80629 (2013).
Amor, A. et al. Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. AIDS 20, 1460–1462 (2006).
Moyer, V. A. & U.S. Preventative Services Task Force. Screening for HIV: U.S. Preventive Services Task Force Recommended Statement. Ann. Intern. Med. 159, 51–60 (2013).
World Health Organization. Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations (WHO Press, 2014).
Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 55, 1–17 (2006).
Zetola, N. M. et al. Simplifying consent for HIV testing is associated with an increase in HIV testing and case detection in highest risk groups, San Francisco January 2003–June 2007. PLoS ONE 3, e2591 (2008).
Haukoos, J. S. et al. Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients. JAMA 304, 284–292 (2010).
Baisley, K. et al. Uptake of voluntary counselling and testing among young people participating in an HIV prevention trial: comparison of opt-out and opt-in strategies. PLoS ONE 7, e42108 (2012).
Weller, S. & Davis, K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst. Rev. 1, CD003255 (2002).
Smith, D. K., Herbst, J. H., Zhang, X. & Rose, C. E. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J. Acquir. Immune Defic. Syndr. 68, 337–344 (2015).
Remis, R. S., Alary, M., Liu, J., Kaul, R. & Palmer, R. W. HIV transmission among men who have sex with men due to condom failure. PLoS ONE 9, e107540 (2014).
Aspinall, E. J. et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int. J. Epidemiol. 43, 235–248 (2014).
Nduati, R., Mbori-Ngacha, D., John, G., Richardson, B. & Kreiss, J. Breastfeeding in women with HIV. JAMA 284, 956–957 (2000).
de Vincenzi, I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect. Dis. 11, 171–180 (2011).
Mofenson, L. M. Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection. Clin. Infect. Dis. 50, S130–S148 (2010).
World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach (WHO Press, 2013). WHO guidelines for a public health approach to ART provision have been crucial in guiding the rollout of ART. The most recent guidelines expanded the eligibility criteria for ART initiation substantially.
Auvert, B. et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2, e298 (2005).
Bailey, R. C. et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369, 643–656 (2007).
Gray, R. H. et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369, 657–666 (2007).
Gray, R. H. et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. Aids 26, 609–615 (2012).
Wawer, M. J. et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 374, 229–237 (2009).
Gray, R. H. et al. Effects of genital ulcer disease and herpes simplex virus type 2 on the efficacy of male circumcision for HIV prevention: analyses from the Rakai trials. PLoS Med. 6, e1000187 (2009).
UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention. Male circumcision for HIV prevention in high HIV prevalence settings: what can mathematical modelling contribute to informed decision making? PLoS Med. 6, e1000109 (2009).
Goodreau, S. M. et al. Can male circumcision have an impact on the HIV epidemic in men who have sex with men? PLoS ONE 9, e102960 (2014).
Cohen, M. S. et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365, 493–505 (2011). This paper presents a randomized controlled trial of early versus standard initiation of ART to prevent transmission of HIV to an uninfected sexual partner.
Rodger, A. et al. Abtract 153LB: HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study. NAPWHA[online], (2014).
Grulich, A. E. et al. HIV transmission in male serodiscordant couples in Australia, Thailand and Brazil. CROI[online], (2015).
Mujugira, A. et al. HIV-1 transmission risk persists during the first 6 months of antiretroviral therapy. CROI[online], (2015).
Gardner, L. I. et al. Time above 1500 copies/ml: a viral-load measure for assessing transmission risk of HIV-positive patients in care. AIDS 29, 947–954 (2015).
Tsai, C. C. et al. Prevention of SIV infection in macaques by (R)-9-(2- phosphonylmethoxypropyl)adenine. Science 270, 1197–1199 (1995).
Cardo, D. M. et al. A case–control study of HIV seroconversion in health care workers after percutaneous exposure. N. Engl. J. Med. 337, 1485–1490 (1997).
Kuhar, D. T. et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect. Control Hosp. Epidemiol. 34, 875–892 (2013). These are the most recent guidelines for post-exposure prophylaxis in the United States.
Joyce, P. M., Kuhar, D. & Brooks, J. T. Occupationally acquired HIV infection by healthcare personnel – United States, 1985–2013 (poster). CROI[online], (2015).
McCormack, S. & Dunn, D. Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD study. CROI[online], (2015).
Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399–410 (2012).
Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587–2599 (2010).
Choopanya, K. et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381, 2083–2090 (2013).
Marrazzo, J. M. et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 372, 509–518 (2015).
Van Damme, L. et al. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367, 411–422 (2012).
Anderson, P. L. et al. Emtricitabine–tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci. Transl. Med. 4, 151ra125 (2012). This paper explores the potential ‘forgiveness’ of less than daily dosing of TDF/FTC pre-exposure prophylaxis.
Kashuba, A. D. et al. Genital tenofovir concentrations correlate with protection against HIV infection in the CAPRISA 004 trial. J. Acquir. Immine Defic. Syndr. 69, 264–269 (2015).
Molina, J. M. et al. On demand PrEP with oral TDF–FTC in MSM: results of the ANRS Ipergay trial. CROI[online], (2015).
World Health Organization. Guidance on Oral Pre-Exposure Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women Who Have Sex with Men at High Risk of HIV (WHO Press, 2012).
Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR 60, 65–68 (2011). These are the most recent pre-exposure prophylaxis guidelines from the Centers for Disease Control and Prevention.
Smith, D. et al. Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR 62, 463–465 (2013).
National Institute of Allergy and Infectious Diseases. Evaluating the safety, tolerability, and pharmacokinetics of an investigational, injectable HIV medicine (GSK1265744) in HIV-uninfected adults. ClinicalTrials.gov[online], (2014).
International Partnership for Microbicides, Inc. Safety and efficacy trial of a dapivirine vaginal matrix ring in healthy HIV-negative women. ClinicalTrials.gov[online], (2012).
International Partnership for Microbicides, Inc. Phase 3 safety and effectiveness trial of dapivirine vaginal ring for prevention of HIV-1 in women (ASPIRE). ClinicalTrials.gov[online], (2012).
Tellalian, D., Maznavi, K., Bredeek, U. F. & Hardy, W. D. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS 27, 553–559 (2013).
Barouch, D. H. & Picker, L. J. Novel vaccine vectors for HIV-1. Nat. Rev. Microbiol. 12, 765–771 (2014).
Haynes, B. F. & Bradley, T. Broadly neutralizing antibodies and the development of vaccines. JAMA 313, 2419–2420 (2015). This is an excellent and clear summary of the search for correlates of protection from a successful HIV vaccine trial.
Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104 (2013).
Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).
Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).
Hallett, T. B. et al. Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS ONE 3, e2212 (2008). This paper demonstrates the potential for synergies from combining different prevention modalities.
HIV Prevention Trials Network. Population effects of antiretroviral therapy to reduce HIV Transmission (PopART). ClinicalTrials.gov[online], (2013).
Mallal, S. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568–579 (2008).
Sabin, C. A. et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371, 1417–1426 (2008).
Taiwo, B. et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 25, 2113–2122 (2011).
Cahn, P. et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect. Dis. 14, 572–580 (2014).
Clotet, B. et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 383, 2222–2231 (2014).
Walmsley, S. L. et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N. Engl. J. Med. 369, 1807–1818 (2013).
Raffi, F. et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect. Dis. 13, 927–935 (2013).
Lennox, J. L. et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann. Intern. Med. 161, 461–471 (2014).
Rockstroh, J. K. et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin. Infect. Dis. 53, 807–816 (2011).
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSinfo[online], (2015).
Mollan, K. R. et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann. Intern. Med. 161, 1–10 (2014).
Puls, R. et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 383, 1474–1482 (2014).
Cohen, C. et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS 28, 989–997 (2014).
Günthard, H. F. et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 312, 410–425 (2014).
Acosta, E. P. et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob. Agents Chemother. 56, 5938–5945 (2012).
Friis-Møller, N. et al. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356, 1723–1735 (2007).
Severe, P. et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N. Engl. J. Med. 363, 257–265 (2010).
Grinsztejn, B. et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect. Dis. 14, 281–290 (2014).
Emery, S. et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J. Infect. Dis. 197, 1133–1144 (2008).
Williams, I. et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 13, S1–S85 (2012).
The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N. Engl. J. Med. 373, 808–822 (2015).
The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N. Engl. J. Med. 373, 795–807 (2015).
Hatano, H. et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog. 9, e1003691 (2013).
Paredes, R. et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J. Infect. Dis. 201, 662–671 (2010).
Deeks, S. G. et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344, 472–480 (2001).
Bangsberg, D. R. et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20, 223–231 (2006).
Little, S. J. et al. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347, 385–394 (2002).
Vercauteren, J. et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J. Infect. Dis. 200, 1503–1508 (2009).
Rhee, S. Y. et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 12, e1001810 (2015).
Pham, Q. D., Wilson, D. P., Law, M. G., Kelleher, A. D. & Zhang, L. Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS 28, 2751–2762 (2014).
Miners, A. et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV 1, e32–e40 (2014).
Phillips, A. N., Neaton, J. & Lundgren, J. D. The role of HIV in serious diseases other than AIDS. AIDS 22, 2409–2418 (2008).
Deeks, S. G., Lewin, S. R. & Havlir, D. V. The end of AIDS: HIV infection as a chronic disease. Lancet 382, 1525–1533 (2013).
Freiberg, M. S. et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern. Med. 173, 614–622 (2013).
Kuller, L. H. et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5, e203 (2008). This retrospective analysis of a randomized clinical trial provides the first definitive evidence that HIV-mediated inflammation predicted development of non-AIDS morbidity and mortality that is independent of other factors.
Worm, S. W. et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect. Dis. 201, 318–330 (2010).
Ryom, L. et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J. Infect. Dis. 207, 1359–1369 (2013).
Deeks, S. G., Tracy, R. & Douek, D. C. Systemic effects of inflammation on health during chronic HIV infection. Immunity 39, 633–645 (2013).
Brothers, T. D. et al. Frailty in people aging with human immunodeficiency virus (HIV) infection. J. Infect. Dis. 210, 1170–1179 (2014).
Althoff, K. N. et al. Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J. Gerontol. A Biol. Sci. Med. Sci. 69, 189–198 (2014).
Rosen, S., Fox, M. P. & Gill, C. J. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 4, e298 (2007).
Fox, M. P. & Rosen, S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop. Med. Int. Health 15, 1–16 (2010).
Fox, M. P. & Rosen, S. Retention of adult patients on antiretroviral therapy in low-and middle-income countries: systematic review and meta-analysis 2008–2013. J. Acquir. Immune Defic. Syndr. 69, 98–108 (2015).
Bradley, H. et al. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV — United States, 2011. MMWR 63, 1113–1117 (2014).
University of California, San Francisco. Sustainable East Africa research in community health (SEARCH). ClinicalTrials.gov[online], (2013).
Centers for Disease Control and Prevention. Botswana Combination Prevention Project (BCPP). ClinicalTrials.gov[online], (2013).
Inserm-ANRS. Impact of immediate versus South African recommendations guided ART initiation on HIV incidence (TasP). ClinicalTrials.gov[online], (2012).
Phillips, A. N. et al. Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. AIDS 29, 1855–1862 (2015).
Thompson, M. A. et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann. Intern. Med. 156, 817–833 (2012).
Andrews, C. D. et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci. Transl. Med. 7, 270ra274 (2015).
Burton, D. R. & Mascola, J. R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571–576 (2015).
Picker, L. J., Hansen, S. G. & Lifson, J. D. New paradigms for HIV/AIDS vaccine development. Annu. Rev. Med. 63, 95–111 (2012). This paper outlines the challenges and potential strategies for developing an effective HIV vaccine.
Hansen, S. G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523–527 (2011). This elegant study demonstrated that a vaccine could induce potent SIV-specific effector CD8+ T cells and that these cells can eradicate established retroviral infection.
Fauci, A. S., Marston, H. D. & Folkers, G. K. An HIV cure: feasibility, discovery, and implementation. JAMA 312, 335–336 (2014).
Hutter, G. et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692–698 (2009). This provocative case report demonstrated that HIV infection can be cured with a haematopoietic stem cell transplant and has inspired a robust international effort to develop a curative intervention.
Yukl, S. A. et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 9, e1003347 (2013).
Sáez-Cirión, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 9, e1003211 (2013).
UN Joint Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. UNAIDS[online], (2013).
Jewkes, R. K., Dunkle, K., Nduna, M. & Shai, N. Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study. Lancet 376, 41–48 (2010).
Centers for Disease Control and Prevention. Statistics Center — HIV/AIDS. CDC[online], (2015).
Gandhi, M. et al. Does patient sex affect human immunodeficiency virus levels? Clin. Infect. Dis. 35, 313–322 (2002).
Chang, J. J. et al. Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J. Infect. Dis. 208, 830–838 (2013).
Triant, V. A., Lee, H., Hadigan, C. & Grinspoon, S. K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with HIV disease. J. Clin. Endocrinol. Metab. 92, 2506–2512 (2007).
Soon, G. G. et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy. AIDS Patient Care STDS 26, 444–453 (2012).
Currier, J. et al. Sex-based outcomes of darunavir–ritonavir therapy: a single-group trial. Ann. Intern. Med. 153, 349–357 (2010).
Loutfy, M. R. et al. Caring for women living with HIV: gaps in the evidence. J. Int. AIDS Soc. 16, 18509 (2013).
Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. AIDSinfo[online], (2015).
Marinda, E. et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr. Infect. Dis. J. 26, 519–526 (2007).
Violari, A. et al. Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med. 359, 2233–2244 (2008).
Puthanakit, T. et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect. Dis. 12, 933–941 (2012).
Hazra, R., Siberry, G. K. & Mofenson, L. M. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu. Rev. Med. 61, 169–185 (2010).
Ranasinghe, S. et al. Association of HLA-DRB1-restricted CD4+ T cell responses with HIV immune control. Nat. Med. 19, 930–933 (2013).
Migueles, S. A. et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29, 1009–1021 (2008).
Ferre, A. L. et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 113, 3978–3989 (2009).
Lelic, A. et al. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog. 8, e1003076 (2012).
Martin, M. P. et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39, 733–740 (2007).
Emu, B. et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J. Virol. 82, 5398–5407 (2008).
Miura, T. et al. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J. Virol. 83, 140–149 (2009).
Chen, H. et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J. Clin. Invest. 121, 1549–1560 (2011).
Abdel-Mohsen, M. et al. Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology 10, 106 (2013).
Mocroft, A. et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 370, 407–413 (2007).
Baker, J. V. et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 22, 841–848 (2008).
Lichtenstein, K. A. et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin. Infect. Dis. 51, 435–447 (2010).
Serrano-Villar, S. et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 10, e1004078 (2014).
Hunt, P. W. et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J. Infect. Dis. 210, 1228–1238 (2014).
Tenorio, A. R. et al. Soluble markers of inflammation and coagulation, but not T-cell activation, are predictors of non-AIDS-defining morbid events during suppressive antiretroviral treatment. J. Infect. Dis. 210, 1248–1259 (2014).
Kelley, C. F. et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin. Infect. Dis. 48, 787–794 (2009).
Okulicz, J. F. et al. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern. Med. 175, 88–99 (2015).
Schneider, E. et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years — United States, 2008. MMWR 57, 1–12 (2008).
Gulick, R. M. et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734–739 (1997).
Engelman, A. & Cherepanov, P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat. Rev. Microbiol. 10, 279–290 (2012).
Brenchley, J. M., Price, D. A. & Douek, D. C. HIV disease: fallout from a mucosal catastrophe? Nat. Immunol. 7, 235–239 (2006).
Bonyhadi, M. L. et al. HIV induces thymus depletion in vivo. Nature 363, 728–732 (1993).
Favre, D. et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2, 32ra36 (2010).
Sauce, D. et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 117, 5142–5151 (2011).
Patel, P. et al. Estimating per-act HIV transmission risk: a systematic review. AIDS 28, 1509–1519 (2014).
The authors thank E. Abrams, J. Gallant, M. Gandhi, E. Geng, T. Ruel and S. Pillai for advice.
S.G.D. has consulted for Bristol-Myers Squibb, GlaxoSmithKline, Novartis and Janssen, and has received research support from Gilead and Merck. A.P. has attended various advisory boards, has received speaker fees for meetings in the past 4 years for Gilead Sciences and has received research support from GlaxoSmithKline. J.O. and S.B. declare no competing interests.
About this article
Cite this article
Deeks, S., Overbaugh, J., Phillips, A. et al. HIV infection. Nat Rev Dis Primers 1, 15035 (2015). https://doi.org/10.1038/nrdp.2015.35
Molecular Immunology (2020)
Seminars in Cell & Developmental Biology (2019)
HIV and HCV augments inflammatory responses through increased TREM-1 expression and signaling in Kupffer and Myeloid cells
PLOS Pathogens (2019)
Nature Reviews Cardiology (2019)
International Journal of Genomics (2019)